Biotech industry veteran to lead Tagworks as the company prepares to bring its novel platform and lead antibody-drug conjugate (ADC) program for solid tumors into the clinic in 2025

We are excited to announce a recent addition to our rapidly expanding team: Krisztina Nemenyi has joined as our Vice President Regulatory Affairs.

We are pleased to announce the appointment of Bianca Matthee as our VP of Research Operations.

We are pleased to announce the recent appointments of Maria V. Cincotta as our VP of Clinical Operations & Program Management and Tu-Anh T. Bui as our VP of CMC & Technical Operations.

Financing round led by Ysios Capital and Gilde Healthcare with participation from Novartis Venture Fund, New Enterprise Associates, and Lightstone Ventures Unique Click-to-Release platform enables on-target activation of antibody-drug conjugates (ADCs) and immunomodulators, as well as off-target deactivation of radiopharmaceuticals Proceeds will be used to advance the lead program, a …

Tagworks announces the completion of an investment round led by Meneldor (The Netherlands), Oost NL (The Netherlands), and a syndicate of high net-worth private investors. The proceeds of the financing will be used for the clinical development of Tagworks' lead program.    

A key patent that encompasses the therapeutic application scope of the Click-to-Release platform has been granted in the US (US 10,967,069 B2), further strengthening Tagworks’ IP portfolio. The patent titled “BIO-ORTHOGONAL DRUG ACTIVATION”, covers the invention of the pyridazine elimination reaction that underlies the Click-to-Release approach. The patent protects a …

Tagworks reports the development of a new and highly reactive Click-to-Release reaction in the Journal of the American Chemical Society. Great collaboration between Tagworks and SyMO-Chem, Syncom, TU/e , Avipep and Levena. https://pubs.acs.org/doi/abs/10.1021/jacs.0c00531

Tagworks is pleased to announce that on the 10th of October, it won the World ADC Award for Best Publication during the 10th World ADC Summit 2019 in San Diego. The World ADC Awards exist to commend excellence across nine categories within antibody-drug conjugate research and development. Tagworks applies its Click-to-Release platform …

In mouse models of ovarian and aggressive colon cancer, Tagworks Pharmaceuticals has demonstrated the potent antitumour effect of the company's 'click-to-release' bioorthogonal chemistry approach. The results are published in the journal Nature Communications Raffaella Rossin, et al., Chemically triggered drug release from an antibody-drug conjugate leads to potent antitumour activity …